

A

DOCKET NO. : ISIS-2710

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of:

Achim H. Krotz and Vasulinga T.  
Ravikumar

Serial No.: Not Yet Assigned

Group Art Unit: Not Yet Assigned

Filing Date: Herewith

Examiner: Not Yet Assigned

For: IMPROVED PROCESS FOR SYNTHESIS OF OLIGONUCLEOTIDES

EXPRESS MAIL LABEL NO: EM155772072US  
DATE OF DEPOSIT: January 26, 1998

Box ☒ Patent Application  
☐ Provisional ☐ Design ☐ Sequence

Assistant Commissioner for Patents  
Washington DC 20231

Sir:

PATENT APPLICATION TRANSMITTAL LETTER

Transmitted herewith for filing, please find

☒ A Utility Patent Application.

If this is a continuing application, please check appropriate box:

☐ continuation ☐ divisional ☐ continuation-in-part of prior application number  
\_\_\_\_/\_\_\_\_.

- ☐ A Provisional Patent Application.
- ☐ A Design Patent Application (submitted in duplicate).

Including the following:

- ☐ Provisional Application Cover Sheet.
- ☒ New or Revised Specification, including pages 1 to 36 containing:

- ☒ Specification
- ☒ Claims
- ☒ Abstract

- ☐ A copy of earlier application Serial No. \_\_\_\_\_ Filed \_\_\_\_\_ to which no new matter has been added TOGETHER WITH a copy of the executed oath or declaration for such earlier application and all drawings and appendices. Such earlier application is hereby incorporated into the present application by reference.

- ☐ Please enter the following amendment to the Specification under the Cross Reference to Related Applications section (or create such a section) : "This Application is a ☐ continuation or ☐ divisional of Application Serial No. \_\_\_\_\_ filed \_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_."

- ☐ Signed Statement attached deleting inventor(s) named in the prior application.

- ☐ A Preliminary Amendment.

- ☐ \_\_\_\_\_ Sheets of ☐ Formal ☐ Informal Drawings.

- ☐ Petition to Accept Photographic Drawings.

- ☐ Petition Fee

- ☒ An ☐ Executed ☒ Unexecuted Declaration or Oath and Power of Attorney.
- ☐ An Associate Power of Attorney.
- ☐ An ☐ Executed ☐ Copy of Executed Assignment of the Invention to \_\_\_\_\_  
\_\_\_\_\_.
- ☐ ☐ A Recordation Form Cover Sheet.
- ☐ ☐ Recordation Fee - \$40.00.
- ☐ Priority is claimed under 35 U.S.C. § 119 of application Serial No. \_\_\_\_\_ filed \_\_\_\_\_  
\_\_\_\_\_ in \_\_\_\_\_ (country).
- ☐ A Certified Copy of each of the following applications for which priority is claimed:
- ☐ is enclosed.
- ☐ has been filed in prior application Serial No. \_\_\_\_\_ filed \_\_\_\_\_.
- ☒ An ☒ Executed ☐ Unexecuted ☒ Statement Claiming Small Entity Status under 37 C.F.R. 1.9 and 1.27
- ☒ is enclosed.
- ☐ has been filed in prior application Serial No. \_\_\_\_\_ filed \_\_\_\_\_, said status is still proper and desired in present case.
- ☐ Diskette Containing DNA/Amino Acid Sequence Information.
- ☐ Statement to Support Submission of DNA/Amino Acid Sequence Information.
- ☐ Letter of Reference to Computer Readable Form.
- ☐ Information Disclosure Statement.
- ☐ Attached Form 1449.
- ☐ Copies of each of the references listed on the attached Form PTO-1449 are enclosed herewith.
- ☐ A copy of Petition for Extension of Time as filed in the prior case.

☐ Appended Material as follows: \_\_\_\_\_

☒ Return Receipt Postcard (should be specifically itemized).

☐ Other as follows: \_\_\_\_\_

**FEE CALCULATION**

				SMALL ENTITY		NOT SMALL ENTITY	
				RATE	FEE	RATE	FEE
PROVISIONAL APPLICATION				\$75.00	\$	\$150.00	\$
DESIGN APPLICATION				\$165.00	\$	\$330.00	\$
UTILITY APPLICATIONS BASE FEE				\$395.00	\$395	\$790.00	\$
UTILITY APPLICATION; ALL CLAIMS CALCULATED AFTER ENTRY OF ALL AMENDMENTS							
	No. Filed	No. Extra					
TOTAL CLAIMS	41 - 20 =	21		\$11 each	\$231	\$22 each	\$
INDEP. CLAIMS	2 - 3 =	0		\$41 each	\$0	\$82 each	\$
FIRST PRESENTATION OF MULTIPLE DEPENDENT CLAIM				\$135	\$0	\$270	\$
ADDITIONAL FILING FEE					\$231		\$
TOTAL FILING FEE DUE					\$626		\$

☒ Two (2) Checks are enclosed in the amounts of \$ 604 & \$22 totaling \$626.


☒ The Commissioner is hereby requested to grant an extension of time for the appropriate length of time, should one be necessary, in connection with this filing or any future filing submitted to the U.S. Patent and Trademark Office in the above-identified application during the pendency of this application. The Commissioner is further authorized to charge any fees related to any such extension of time to deposit account 23-3050. This sheet is provided in duplicate.

☒ The Commissioner is authorized to charge payment of the following fees and to refund any overpayment associated with this communication or during the pendency of this application to deposit account 23-3050. This sheet is provided in duplicate.

- ☐ The foregoing amount due.
- ☒ Any additional filing fees required, including fees for the presentation of extra claims under 37 C.F.R. 1.16.
- ☒ Any additional patent application processing fees under 37 C.F.R. 1.17 or 1.20(d).
- ☐ The issue fee set in 37 C.F.R. 1.18 at the mailing of the Notice of Allowance.

**SHOULD ANY DEFICIENCIES APPEAR** with respect to this application, including deficiencies in payment of fees, missing parts of the application or otherwise, the United States Patent and Trademark Office is respectfully requested to promptly notify the undersigned.

Date: February 26, 1998

  
\_\_\_\_\_  
Michael P. Straher  
Registration No. 38,325

Woodcock Washburn Kurtz  
Mackiewicz & Norris LLP  
One Liberty Place - 46th Floor  
Philadelphia PA 19103  
Telephone: (215) 568-3100  
Facsimile: (215) 568-3439

## IMPROVED METHODS FOR SYNTHESIS OF OLIGONUCLEOTIDES

## FIELD OF THE INVENTION

The present invention is directed to improved methods for synthesis of oligonucleotides and other  
5 phosphorus-linked oligomers, using aromatic solvents, alkyl  
aromatic solvents, halogenated aromatic solvents,  
halogenated alkyl aromatic solvents, or aromatic ether  
solvents. Oligomers synthesized using the methods of the  
invention are useful for diagnostic reagents, research  
10 reagents and in therapeutics.

## BACKGROUND OF THE INVENTION

It is well known proteins are significantly  
involved in many of the bodily states in multicellular  
organisms, including most disease states. Such proteins,  
15 either acting directly or through their enzymatic or other  
functions, contribute in major proportion to many diseases  
and regulatory functions in animals and man. For disease  
states, classical therapeutics has generally focused upon  
interactions with such proteins in efforts to moderate their  
20 disease-causing or disease-potentiating functions. In newer  
therapeutic approaches, modulation of the production of such  
proteins is desired. By interfering with the production of  
proteins, the maximum therapeutic effect might be obtained  
with minimal side effects. It is the general object of such  
25 therapeutic approaches to interfere with or otherwise

modulate gene expression which would lead to undesired protein formation.

One method for inhibiting specific gene expression is with the use of oligonucleotides, especially oligonucleotides which are complementary to a specific target messenger RNA (mRNA) sequence.

Transcription factors interact with double-stranded DNA during regulation of transcription. Oligonucleotides can serve as competitive inhibitors of transcription factors to modulate the action of transcription factors. Several recent reports describe such interactions (see Bielinska, A., et. al., *Science*, 1990, 250, 997-1000; and Wu, H., et. al., *Gene*, 1990, 89, 203-209).

In addition to functioning as both indirect and  
15 direct regulators of proteins, oligonucleotides have also  
found use in diagnostic tests. Such diagnostic tests can be  
performed using biological fluids, tissues, intact cells or  
isolated cellular components. As with gene expression  
inhibition, diagnostic applications utilize the ability of  
20 oligonucleotides to hybridize with a complementary strand of  
nucleic acid. Hybridization is the sequence specific  
hydrogen bonding of oligonucleotides, via Watson-Crick  
and/or Hoogsteen base pairs, to RNA or DNA. The bases of  
such base pairs are said to be complementary to one another.

25           Oligonucleotides are also widely used as research reagents. They are useful for understanding the function of many other biological molecules as well as in the preparation of other biological molecules. For example, the use of oligonucleotides as primers in polymerase chain  
30 reactions (PCR) has given rise to an expanding commercial industry. PCR has become a mainstay of commercial and research laboratories, and applications of PCR have multiplied. For example, PCR technology is used in the fields of forensics, paleontology, evolutionary studies and  
35 genetic counseling. Commercialization has led to the development of kits which assist non-molecular biology-trained personnel in applying PCR. Oligonucleotides, both

natural and synthetic, are employed as primers in PCR technology.

Laboratory uses of oligonucleotides are described generally in laboratory manuals such as *Molecular Cloning, A Laboratory Manual*, Second Ed., J. Sambrook, et al., Eds., Cold Spring Harbor Laboratory Press, 1989; and *Current Protocols In Molecular Biology*, F. M. Ausubel, et al., Eds., Current Publications, 1993. Such uses include Synthetic Oligonucleotide Probes, Screening Expression Libraries with Antibodies and Oligonucleotides, DNA Sequencing, In Vitro Amplification of DNA by the Polymerase Chain Reaction and Site-directed Mutagenesis of Cloned DNA (see Book 2 of *Molecular Cloning, A Laboratory Manual, ibid.*) and DNA-Protein Interactions and The Polymerase Chain Reaction (see Vol. 2 of *Current Protocols In Molecular Biology, ibid.*).

Oligonucleotides can be custom-synthesized for a desired use. Thus a number of chemical modifications have been introduced into oligonucleotides to increase their usefulness in diagnostics, as research reagents and as therapeutic entities. Such modifications include those designed to increase binding to a target strand (i.e. increase their melting temperatures, (T<sub>m</sub>)); to assist in identification of the oligonucleotide or an oligonucleotide-target complex; to increase cell penetration; to stabilize against nucleases and other enzymes that degrade or interfere with the structure or activity of the oligonucleotides; to provide a mode of disruption (terminating event) once sequence-specifically bound to a target; and to improve the pharmacokinetic properties of the oligonucleotides.

Thus, it is of increasing value to prepare oligonucleotides and other phosphorus-linked oligomers for use in basic research or for diagnostic or therapeutic applications. Consequently, and in view of the considerable expense and time required for synthesis of specific oligonucleotides, there has been a longstanding effort to develop successful methodologies for the preparation of



specific oligonucleotides with increased efficiency and product purity.

Synthesis of oligonucleotides can be accomplished using both solution phase and solid phase methods.

5 Oligonucleotide synthesis via solution phase in turn can be accomplished with several coupling mechanisms. However, solution phase chemistry requires purification after each internucleotide coupling, which is labor intensive and time consuming.

10 The current method of choice for the preparation of naturally occurring oligonucleotides, as well as modified oligonucleotides such as phosphorothioate and phosphorodithioate oligonucleotides, is via solid-phase synthesis wherein an oligonucleotide is prepared on a polymer support  
15 (a solid support) such as controlled pore glass (CPG); oxalyl-controlled pore glass (see, e.g., Alul, et al., *Nucleic Acids Research* 1991, 19, 1527); TENTAGEL Support, (see, e.g., Wright, et al., *Tetrahedron Letters* 1993, 34, 3373); or POROS, a polystyrene resin available from  
20 Perceptive Biosystems.

Solid-phase synthesis relies on sequential addition of nucleotides to one end of a growing oligonucleotide chain. Typically, a first nucleoside (having protecting groups on any exocyclic amine functionalities present) is  
25 attached to an appropriate glass bead support and activated phosphite compounds (typically nucleotide phosphoramidites, also bearing appropriate protecting groups) are added stepwise to elongate the growing oligonucleotide. The nucleotide phosphoramidites are reacted with the growing  
30 oligonucleotide using "fluidized bed" technology to mix the reagents. The known silica supports suitable for anchoring the oligonucleotide are very fragile and thus cannot be exposed to aggressive mixing. Brill, W. K. D., et al. *J. Am. Chem. Soc.*, 1989, 111, 2321, disclosed a procedure  
35 wherein an aryl mercaptan is substituted for the nucleotide phosphoramidite to prepare phosphorodithioate oligonucleotides on glass supports.



phosphoro-dithioate as a major product and a derivative suitable for preparation of a phosphorithioate as a minor product.

Further details of methods useful for preparing  
5 oligonucleotides may be found in Sekine, M., et al., *J.*  
*Org. Chem.*, 1979, 44, 2325; Dahl, O., *Sulfur Reports*, 1991,  
11, 167-192; Kresse, J., et al. ., *Nucleic Acids Research*,  
1975, 2, 1-9; Eckstein, F., *Ann. Rev. Biochem.*, 1985, 54,  
367-402; and Yau, E.K. U.S. Patent No. 5,210,264.

Methods for synthesizing oligonucleotides using intermediates having phosphorus-containing covalent linkages involve the protection of the 5'-hydroxyl group of a nucleoside by forming trityl or substituted trityl or triarylmethyl derivatives. The protecting groups are later removed under acidic conditions to yield the free 5'-hydroxyl group. The hydroxyl group can then be further reacted to give a coupled product.

The removal of trityl and other protecting groups is generally carried out in the presence of halogenated solvents such as dichloromethane or dichloroethane. However, the use of such halogenated solvents is undesirable for several reasons, particularly in relatively large scale applications such as the manufacture of oligonucleotides or analogs use as antisense agents. Consequently, there remains a need for methods of synthesis of oligonucleotides which provide improved efficiency and reduced disposal problems. The present invention is directed to these, as well as other, important ends.

## SUMMARY OF THE INVENTION

30           The present invention provides improved methods for  
the preparation of oligonucleotides.

In some preferred embodiments the present invention provides methods for the preparation of a phosphorus-linked oligomer comprising the steps of:

- 35           (a) providing a solid support;  
             (b) attaching a 5'-O-protected nucleoside to the

solid support;

5

10

phosphorodithioate or H-phosphonate linkage;

15

(g) cleaving the oligomer from the solid support.

20

25

30

35

with chlorobenzene or benzotrifluoride being especially preferred.

In some preferred embodiments of the methods of the invention the activated phosphorus compound is an activated  
5 mononucleotide, an activated dinucleotide, or an activated polynucleotide.

In further preferred embodiments of the method of the invention, the activated phosphorus compound is a 5'-protected nucleoside phosphoramidite or a 5'-protected  
10 activated H-phosphonate nucleoside.

In some preferred embodiments of the methods of the invention, the 5'-protecting group of the 5'-O-protected nucleoside and the 5'-protected activated phosphorus compound is independently trityl, monomethoxy trityl,  
15 dimethoxytrityl, trimethoxytrityl, 2-chlorotrityl, DATE, TBTr, Pixyl or Moxyl, with trityl, monomethoxy trityl, dimethoxy trityl, 9-phenylxanthine-9-yl (Pixyl) or 9-(p-methoxyphenyl)xanthine-9-yl MOX) being more preferred, and dimethoxy trityl being especially preferred.

20 In some preferred embodiments of the methods of the invention, the phosphorus-linked oligomer is a phosphodiester, phosphorothioate phosphorodithioate, or H-phosphonate oligonucleotide.

In some preferred embodiments of the methods of the invention, the protic acid is formic acid, acetic acid,  
25 chloroacetic acid, dichloroacetic acid, trichloroacetic acid, trifluoroacetic acid, benzenesulfonic acid, toluenesulfonic acid, or phenylphosphoric acid.

In further preferred embodiments the solvent in  
30 step (c) further comprises an additive, which is preferably an alcohol, with from 0% to about 30% methanol, ethanol, 2-propanol, t-butyl alcohol, t-amyl alcohol, benzyl alcohol, or 1,1,1,3,3,3-hexafluoro-2-propanol, or a mixture thereof being especially preferred.

35 In some further preferred embodiments, the 5'-protected activated phosphorus compound is a 5'-protected activated H-phosphonate compound; and the phosphorus-linked

866060 2/62E060

oligomer is a H-phosphonate oligonucleotide.

In some preferred embodiments, the present invention provides methods for the preparation of a phosphorus-linked oligomer comprising the steps of:

- 5 a) providing a solid support;  
b) attaching a 5'-O-protected nucleoside to the solid support;  
c) contacting the protected 5'-hydroxyl of the nucleoside with a deprotecting reagent comprising a protic  
10 acid in a solvent to deprotect the 5'-hydroxyl of the nucleoside, the solvent being an aromatic solvent, an alkyl aromatic solvent, a halogenated aromatic solvent, a halogenated alkyl aromatic solvent, or an aromatic ether solvent;  
15 d) reacting the deprotected 5'-hydroxyl with a 5'-protected activated phosphite compound to produce a phosphite linkage;  
e) oxidizing or sulfurizing the phosphite linkage to form a phosphodiester, phosphorothioate, or  
20 phosphorodithioate linkage;  
f) repeating steps c through e at least once for subsequent couplings of additional activated phosphite compounds, to produce the completed phosphorus-linked oligomer; and  
25 g) cleaving the oligomer from the solid support.

Some preferred embodiments of the methods of the invention further comprise the step of capping remaining reactive sites with a solution containing a capping reagent.

In some preferred embodiments of the methods of the invention, solvent in step (c) is an aromatic solvent, an alkyl aromatic solvent, or an aromatic ether. In more preferred embodiments the solvent in step (c) is benzene, toluene, benzonitrile, *o*-, *m*- or *p*-xylene, mesitylene, or diphenyl ether, with benzene, toluene or *o*-, *m*- or *p*-xylene being more preferred, and toluene being particularly preferred.

In other preferred embodiments of the methods of

the invention, the solvent in step (c) is a halogenated aromatic solvent or a halogenated alkyl aromatic solvent, with chlorobenzene or benztotriufuide being especially preferred.

5           In some preferred embodiments of the methods of the invention the activated phosphorus compound is a mononucleotide phosphoramidite, a dinucleotide phosphoramidite, or a polynucleotide phosphoramidite.

In further preferred embodiments of the method of the invention, the activated phosphorus compound is a 5'-protected nucleoside phosphoramidite or a 5'-protected activated H-phosphonate nucleoside.

In some preferred embodiments of the methods of the invention, the 5'-protecting group of the 5'-O-protected nucleoside and the 5'-protected activated phosphorus compound is independently trityl, monomethoxy trityl, dimethoxytrityl, trimethoxytrityl, 2-chlorotrityl, DATE, TBTr, Pixyl or Moxyl, with trityl, monomethoxy trityl, dimethoxy trityl, 9-phenylxanthine-9-yl (Pixyl) or 9-(p-methoxyphenyl)xanthine-9-yl (MOX) being more preferred, and dimethoxy trityl being especially preferred.

In some preferred embodiments of the methods of the invention, the phosphorus-linked oligomer is a phosphodiester, phosphorothioate or phosphorodithioate oligonucleotide.

In some preferred embodiments of the methods of the invention, the protic acid is formic acid, acetic acid, chloroacetic acid, dichloroacetic acid, trichloroacetic acid, trifluoroacetic acid, benzenesulfonic acid, toluenesulfonic acid, or phenylphosphoric acid.

In further preferred embodiments the solvent in step (c) further comprises an additive, which is preferably an alcohol, with from 0% to about 30% methanol, ethanol, 2-propanol, t-butyl alcohol, t-amyl alcohol, benzyl alcohol, 35 or 1,1,1,3,3,3-hexafluoro-2-propanol, or a mixture thereof being especially preferred.

In some particularly preferred embodiments, the

solvent in step (c) is benzene, toluene, benzonitrile, o-, m- or p-xylene, mesitylene, or diphenyl ether, with toluene being especially preferred; the activated phosphite compound is a mononucleotide phosphoramidite, a dinucleotide  
5 phosphoramidite, or a polynucleotide phosphoramidite; the protecting group of the 5'-O-protected nucleoside and the 5'-protected activated phosphite compound is dimethoxytrityl; the phosphorus linked oligomer is a phosphodiester, phosphorothioate or a phosphorodithioate  
10 oligonucleotide; and the protic acid is dichloroacetic acid.

#### DETAILED DESCRIPTION

The present invention provides novel methods for the preparation of phosphorus-linked oligomers comprising the steps of:


- 15 (a) providing a solid support;
  - (b) attaching a 5'-O-protected nucleoside to the solid support;
  - (c) deprotecting the 5'-hydroxyl of the nucleoside with a deprotecting reagent comprising a protic acid in a  
20 solvent to deprotect the 5'-hydroxyl of the nucleoside, the solvent being an aromatic solvent, an alkyl aromatic solvent, a halogenated aromatic solvent, a halogenated alkyl aromatic solvent, or an aromatic ether solvent;
  - (d) reacting the deprotected 5'-hydroxyl with an  
25 5'-protected activated phosphorus compound to produce a covalent linkage therebetween;
  - (e) oxidizing or sulfurizing the covalent linkage to form a phosphodiester, phosphorothioate, phosphorodithioate or H-phosphonate linkage;
  - 30 (f) repeating steps c through e at least once for subsequent couplings of additional activated phosphorus compounds, to produce the completed phosphorus-linked oligomer; and
  - (g) cleaving the oligomer from the solid support.
- 35 It is generally preferable to perform a capping step after reaction of the deprotected 5'-hydroxyl with an



5'-protected activated phosphorus compound. The capping step can be performed either before or after the oxidation or sulfurization step, and is generally known to provide benefits in the prevention of shortened oligomer chains, by blocking chains that have not reacted in the coupling cycle. One representative reagent used for capping is acetic anhydride. Other suitable capping reagents and methodologies can be found in United States Patent 4,816,571.

The methods of the invention can be used for the preparation of a variety of phosphorus-linked oligonucleotide species, such as phosphodiester, phosphorothioate, phosphorodithioate and H-phosphonate oligonucleotides.

The methods of the invention can be used to prepare several types of oligonucleotides, including phosphodiesters, phosphotriesters, phosphorothioates, phosphodithioates, and H-phosphonates. These oligonucleotides are of the structure:



wherein Z is an acid labile protecting group and B is a naturally occurring nucleobase (i.e., adenine (A), cytosine (C), guanine (G), thymine (T) or uracil (U)) or any of the nucleobase analogs known in the art as described below. For the phosphodiester DNA, X = H, and B = A, C, G, or T; and

for the phosphodiester RNA, X = OH, and B = A, C, G or U. Y is H, OH, SH or alkyl, and L is O or S. T is a solid support as described below for solid phase synthesis or a base labile protecting group for solution phase synthesis

5           In the context of the present invention, the term  
"phosphorus-linked oligomer" refers to a plurality of joined  
nucleobase-bearing sugar moieties connected by a linking  
group having a phosphorus atom. Linking groups include  
phosphodiester, phosphotriester, phosphorothioate,  
10 phosphodithioate, and H-phosphonate linkages.

The structures listed above are representative of commonly synthesized phosphorus-linked oligomers, and the application of the methods of the present invention to them is illustrative, and not limiting. For example, it is known to substitute a wide variety of modifications on the above structures including base modifications, backbone modifications, phosphate modifications, sugar modifications, and 2' modifications. Recent modifications include replacing the sugar with an alternative structure which has primary and a secondary alcohol groups similar to those of ribose. As used herein, these modified compounds are included within the definition of the term "phosphorus-linked oligomers".

As used herein, the term "5'-protected activated  
25 phosphorus compound" is intended to denote a mono-, di- or  
polynucleoside species that has an activated phosphorus group  
at its 3'-terminus, and bears a 5'-hydroxyl protecting  
group. The activated phosphorus group is one that is known  
in the art to undergo a coupling reaction with the  
30 deprotected 5'-hydroxyl of a growing oligomeric chain  
according to standard synthetic methodologies, such as, for  
example, the phosphoramidite, phosphotriester and H-  
phosphonate synthetic methods. See for example Caruthers  
U.S. Patents Nos. 4,415,732; 4,458,066; 4,500,707;  
35 4,668,777; 4,973,679; and 5,132,418; and Koster U.S. Patents  
Nos. 4,725,677 and Re. 34,069; Sekine, M., et al., *J. Org.  
Chem.*, 1979, 44, 2325; Dahl, O., *Sulfur Reports*, 1991, 11,

167-192; Kresse, J., et al. ., *Nucleic Acids Research*, 1975, 2, 1-9; Eckstein, F., *Ann. Rev. Biochem.*, 1985, 54, 367-402; and Yau, E.K. U.S. Patent No. 5,210,264, and *Oligonucleotides and Analogues A Practical Approach*,

5 Eckstein, F. Ed., IRL Press, New York, 1991, each of the disclosures of which are hereby incorporated by reference in their entirety. Thus, activated phosphorus groups include groups of formula  $-P(-O-Pr)-N(i-pr)_2$  where Pr is a phosphorus protecting group useful in phosphoramidite synthesis, such  
10  $\beta$ -cyanoethyl.

In accordance with the methods of the invention, a 5'-O-protected nucleoside synthon is first attached to a solid support. Solid supports are substrates which are capable of serving as the solid phase in solid phase  
15 synthetic methodologies, such as those described in Caruthers U.S. Patents Nos. 4,415,732; 4,458,066; 4,500,707; 4,668,777; 4,973,679; and 5,132,418; and Koster U.S. Patents Nos. 4,725,677 and Re. 34,069. Linkers are known in the art as short molecules which serve to connect a solid support to  
20 functional groups (e.g., hydroxyl groups) of initial synthon molecules in solid phase synthetic techniques. One such linker is a succinamide linker. Other suitable linkers are disclosed in, for example, *Oligonucleotides And Analogues A Practical Approach*, Ekstein, F. Ed., IRL Press, N.Y, 1991,  
25 Chapter 1, pages 1-23.

Solid supports according to the invention include those generally known in the art to be suitable for use in solid phase methodologies, including, for example, controlled pore glass (CPG), oxalyl-controlled pore glass  
30 (see, e.g., Alul, et al., *Nucleic Acids Research* 1991, 19, 1527), TentaGel Support (an aminopolyethyleneglycol derivatized support (see, e.g., Wright, et al., *Tetrahedron Letters* 1993, 34, 3373)) and Poros (a copolymer of polystyrene/divinylbenzene).

35 In accordance with the methods of the invention, after the initial nucleoside synthon is attached to the solid support, the 5'-hydroxyl of the nucleoside deprotected

with a deprotecting reagent, which includes a protic acid in a solvent, and, optionally, an additive.

Heretofore, deblocking of 5'-hydroxyl groups has been accomplished using such protic acids in a halogenated alkyl solvent such as dichloromethane or dichloroethane. However the use of such halogenated alkyl solvents is greatly disadvantageous because they are not easily disposed of (and therefore expensive to use) because of the environmental hazard they pose. For example, methylene chloride has been classified as a carcinogen by OSHA, and such low boiling solvents require a relatively large investment in recycling equipment.

It has been discovered in accordance with the present invention that deblocking reactions can be performed in solvents other than halogenated alkyl solvents. Thus, in accordance with preferred embodiments of the invention, deprotection (i.e., deblocking) of the 5'-O- protecting group is accomplished using a protic acid such as formic acid, acetic acid, chloroacetic acid, dichloroacetic acid, trichloroacetic acid, trifluoroacetic acid, benzenesulfonic acid, toluenesulfonic acid, or phenylphosphoric acid, in an aromatic solvent, an alkyl aromatic solvent, a halogenated aromatic solvent, a halogenated alkyl aromatic solvent, or an aromatic ether solvent.

In more preferred embodiments, the solvent is benzene, toluene, benzonitrile, *o*-, *m*- or *p*-xylene, mesitylene, or diphenyl ether. In still more preferred embodiments the solvent is benzene, toluene or *o*-, *m*- or *p*-xylene, with toluene being particularly preferred.

In some preferred embodiments, the solvent is high boiling; i.e., it has a boiling point greater than about 60°C. Such solvents are additionally advantageous in that they do not require a substantial investment in recycling equipment that meets stringent environmental regulations required by OSHA for lower boiling solvents.

As used herein, the term alkyl includes but is not limited to straight chain, branch chain, and alicyclic

090329Z "030290  
062000" 2262060

5 incorporated by reference in its entirety.

10 where the substituents include halogen, nitro, or  
hydroxymethyl.

15 known to be useful as solvents in the art. These include  
for example, toluene, *o*-, *m*- or *p*-xylene, and mesitylene.  
Also included within the definition of "alkyl aromatic  
solvent" are liquid aromatic ring compounds that contain  
cyano groups, such as benzonitrile.

20 Halogens include fluorine, chlorine, bromine and  
iodine.

25 denotes an aromatic compound having at least one heteroatom (i.e., an atom other than carbon) in the aromatic ring.

30 produce a covalent linkage therebetween. In some preferred  
embodiments wherein the activated phosphorus compound is a  
phosphoramidite, a phosphite linkage is produced. In other  
preferred embodiments, such as in H-phosphonate chemistries,  
the activated phosphorus group has the formula  
35  $-O-HP(=O)-O^-$ , and reacts with a free 3'-hydroxyl of the  
growing oligonucleotide chain in the presence of an  
activating agent such as pivaloyl chloride to produce an

H-phosphonate linkage.

In some preferred embodiments, a sulfurization step or oxidation step is performed after each deprotection-coupling cycle. However, if desired, oxidation or sulfurization can be performed in a single step at the end of the iterative synthesis.

Useful oxidizing agents according to the present invention include iodine, t-butyl hydroperoxide, or other oxidizing reagents known in the art.

Sulfurizing agents used during oxidation to form phosphorothioate linkages include Beaucage reagent (see e.g. Iyer, R.P., et al. ., *J. Chem. Soc.*, 1990, 112, 1253-1254, and Iyer, R.P., et al., *J. Org. Chem.*, 1990, 55, 4693-4699); tetraethylthiuram disulfide (see e.g., Vu, H., Hirschbein, B.L., *Tetrahedron Lett.*, 1991, 32, 3005-3008); dibenzoyl tetrasulfide (see e.g., Rao, M.V., et al. ., *Tetrahedron Lett.*, 1992, 33, 4839-4842); di(phenylacetyl)disulfide (see e.g., Kamer, P.C.J., *Tetrahedron Lett.*, 1989, 30, 6757-6760); 1,2,4-dithiiazoline-5-one (DtsNH) and 3-ethoxy-1,2,4-dithiiazoline-5-one (EDITH) and (see Xu et al., *Nucleic Acids Research*, 1996, 24, 3643-3644 and Xu et al., *Nucleic Acids Research*, 1996, 24, 1602-1607); thiophosphorus compounds such as those disclosed in U.S. patent No. 5,292,875 to Stec et al., and U.S. patent No. 5,151,510 to Stec et al., disulfides of sulfonic acids, such as those disclosed in Efimov et al., *Nucleic Acids Research*, 1995, 23, 4029-4033, sulfur, sulfur in combination with ligands like triaryl, trialkyl, triaralkyl, or trialkaryl phosphines.

30           The deprotection and coupling steps, and,  
optionally, oxidation or sulfurization steps, are repeated  
using mono-, di- or polymeric activated synthons until the  
desired base sequence is achieved. The completed oligomer  
is then cleaved from the solid support. Cleavage is  
35 achieved by any of the standard methods in the art, such as,  
for example, with concentrated ammonium hydroxide.

The methods of the present invention can be used

for the synthesis of phosphorus-linked oligonucleotides having both naturally occurring and non-naturally occurring constituent groups. For example, the present invention can be used to synthesize phosphodiester, phosphorothioate, phosphorodithioate, and H-phosphonate oligomers having naturally occurring pentose sugar components such as ribose and deoxyribose, and their substituted derivatives, as well as other sugars known to substitute therefor in oligonucleotide analogs.

10           The constituent sugars and nucleosidic bases of the phosphorus-linked oligonucleotides can be naturally occurring or non-naturally occurring. Non-naturally occurring sugars and nucleosidic bases are typically structurally distinguishable from, yet functionally interchangeable with, naturally occurring sugars (e.g. ribose and deoxyribose) and nucleosidic bases (e.g., adenine, guanine, cytosine, thymine). Thus, non-naturally occurring nucleobases and sugars include all such structures which mimic the structure and/or function of naturally occurring species, and which aid in the binding of the oligonucleotide to a target, or which otherwise advantageously contribute to the properties of the oligonucleotide.

          The methods of the invention are amenable to the synthesis of phosphorus-linked oligomers having a variety of substituents attached to their 2'-positions. These include, for example, halogens, O-alkyl, O-alkylamino, O-alkylalkoxy, protected O-alkylamino, O-alkylaminoalkyl, O-alkyl imidazole, and polyethers of the formula (O-alkyl)<sub>m</sub>, where m is 1 to about 10. Preferred among these polyethers are linear and cyclic polyethylene glycols (PEGs), and (PEG)-containing groups, such as crown ethers and those which are disclosed by Ouchi, et al., *Drug Design and Discovery* 1992, 9, 93, Ravasio, et al., *J. Org. Chem.* 1991, 56, 4329, and Delgado et. al., *Critical Reviews in Therapeutic Drug* 30 *Carrier Systems* 1992, 9, 249. Further sugar modifications are disclosed in Cook, P.D., *supra*. Fluoro, O-alkyl, O-alkylamino, O-alkyl imidazole, O-alkylaminoalkyl, and alkyl

003297 030298  
8520E0 262E060

amino substitution is described in United States Patent Application serial number 08/398,901, filed March 6, 1995, entitled Oligomeric Compounds having Pyrimidine Nucleotide(s) with 2' and 5' Substitutions, the disclosure of which is hereby incorporated by reference. Further representative O-substitutions on the ribosyl ring include S, CH<sub>2</sub>, CHF, and CF<sub>2</sub>, see, e.g., Secrist, et al., *Abstract 21, Program & Abstracts, Tenth International Roundtable, Nucleosides, Nucleotides and their Biological Applications*, Park City, Utah, Sept. 16-20, 1992.

Representative nucleobases suitable for use in the methods of the invention include adenine, guanine, cytosine, uridine, and thymine, as well as other non-naturally occurring and natural nucleobases such as xanthine, hypoxanthine, 2-aminoadenine, 6-methyl and other alkyl derivatives of adenine and guanine, 2-propyl and other alkyl derivatives of adenine and guanine, 5-halo uracil and cytosine, 6-azo uracil, cytosine and thymine, 5-uracil (pseudo uracil), 4-thiouracil, 8-halo, oxa, amino, thiol, thioalkyl, hydroxyl and other 8-substituted adenines and guanines, 5-trifluoromethyl and other 5-substituted uracils and cytosines, 7-methylguanine. Further naturally and non naturally occurring nucleobases include those disclosed in U.S. Patent No. 3,687,808 (Merigan, et al.), in chapter 15 by Sanghvi, in *Antisense Research and Application*, Ed. S. T. Crooke and B. Lebleu, CRC Press, 1993, in Englisch et al., *Angewandte Chemie*, International Edition, 1991, 30, 613-722 (see especially pages 622 and 623, and in the *Concise Encyclopedia of Polymer Science and Engineering*, J.I. Kroschwitz Ed., John Wiley & Sons, 1990, pages 858-859, Cook, P.D., *Anti-Cancer Drug Design*, 1991, 6, 585-607. The terms "nucleosidic base" and "nucleobase" are further intended to include heterocyclic compounds that can serve as nucleosidic bases, including certain 'universal bases' that are not nucleosidic bases in the most classical sense, but function similarly to nucleosidic bases. One representative example of such a universal base is 3-nitropyrrole.



The methods of the present invention use labile protecting groups to protect various functional moieties during synthesis. Protecting groups are used ubiquitously in standard oligonucleotide synthetic regimes for protection of several different types of functionality. In general, protecting groups render chemical functionality inert to specific reaction conditions and can be appended to and removed from such functionality in a molecule without substantially damaging the remainder of the molecule. See, e.g., Green and Wuts, Protective Groups in Organic Synthesis, 2d edition, John Wiley & Sons, New York, 1991. Representative protecting groups useful to protect nucleotides during synthesis include base labile protecting groups and acid labile protecting groups. Base labile protecting groups are used to protect the exocyclic amino groups of the heterocyclic nucleobases. This type of protection is generally achieved by acylation. Two commonly used acylating groups for this purpose are benzoylchloride and isobutyrylchloride. These protecting groups are stable to the reaction conditions used during oligonucleotide synthesis and are cleaved at approximately equal rates during the base treatment at the end of synthesis.

In some preferred embodiments, the 5'-protected activated phosphorus compound is a nucleoside phosphoramidite. Phosphoramidites of numerous nucleosides and derivatized solid supports are commercially available through various companies (e.g. Applied Biosystems Inc., Millipore Corp.). The amino moiety of such phosphordiamidites can be selected from various amines presently used for phosphoramidites in standard oligonucleotide synthesis. These include both aliphatic and heteroalkyl amines. One preferred amino group is diisopropylamino. Other examples of suitable amines as are described in various United States patents, principally those to M. Caruthers and associates. These include United States patents 4,668,777; 4,458,066; 4,415,732; and 4,500,707; all of which are herein incorporated by

reference.

Hydroxyl protecting groups typically used in oligonucleotide synthesis may be represented by the following structure:



10

20

25

- 30

aromatic solvent, a halogenated aromatic solvent, a halogenated alkyl aromatic solvent, or an aromatic ether solvent;

d) reacting the deprotected 5'-hydroxyl with a 5'-protected activated phosphite compound to produce a phosphite linkage;

e) oxidizing or sulfurizing the phosphite linkage to form a phosphodiester, phosphorothioate, or phosphorodithioate linkage;

f) repeating steps c through e at least once for subsequent couplings of additional activated phosphite compounds, to produce the completed phosphorus-linked oligomer; and

g) cleaving the oligomer from the solid support.

As used herein, the term "activated phosphite compound" is intended to include mono-, di- and polynucleoside phosphoramidites.

As used herein, the term "5'-protected activated phosphite compound" is intended to include a 5'-protected mono-, di- and polynucleoside phosphoramidite, as is used in standard solid phase oligonucleotide synthesis.

In some preferred embodiments of the invention the phosphordiamidite is activated to nucleophilic attack by the 5' hydroxyl by use of an activating agent. It is believed that the activating agent displaces one of the amino groups from the phosphordiamidite, thereby rendering the phosphorus of the phosphordiamidite more susceptible to nucleophilic attack by the 5' hydroxyl group of the growing nucleotide chain. Any activating agent that can activate the phosphorous to nucleophilic attack without interacting with the growing nucleotide chain may be suitable for use with the present invention. One preferred activating agent is tetrazole. Some commonly used commercially available activating agents are thiotetrazole, nitrotetrazole, and N,N-diisopropylaminohydro-tetrazolide. Other suitable activating agents are also disclosed in the above incorporated patents as well as in United States patent

4,725,677 and in Berner, S., Muhlegger, K., and Seliger, H.,  
*Nucleic Acids Research* 1989, 17:853; Dahl, B.H., Nielsen, J.  
and Dahl, O., *Nucleic Acids Research* 1987, 15:1729; and  
Nielson, J. Marugg, J.E., Van Boom, J.H., Honnens, J.,  
5 Taagaard, M. and Dahl, O., *J. Chem. Research* 1986, 26, all  
of which are herein incorporated by reference.

Phosphorus linked oligomers produced by the methods  
of the invention will preferably be hybridizable to a  
specific target oligonucleotide. Preferably, the phosphorus  
10 linked oligomers produced by the methods of the invention  
comprise from about 1 to about 100 monomer subunits. It is  
more preferred that such compounds comprise from about 10 to  
about 30 monomer subunits, with 15 to 25 monomer subunits  
being particularly preferred.

15 As will be recognized, the process steps of the  
present invention need not be performed any particular  
number of times or in any particular sequence. Additional  
objects, advantages, and novel features of this invention  
will become apparent to those skilled in the art upon  
20 examination of the following examples thereof, which are not  
intended to be limiting.

### Example 1

#### Synthesis of 5'-TTTTTT-3' phosphorothioate heptamer

50 milligram (2  $\mu$ mole) of 5'-O-  
25 dimethoxytritylthymidine bound to CPG (controlled pore  
glass) through an ester linkage is taken up in a glass  
reactor, and a toluene solution of 3% dichloroacetic acid  
(volume/volume) is added to deprotect the 5'-hydroxyl group.  
The product is washed with acetonitrile. Then, a 0.2 M  
30 solution of 5'-O-(4,4'-dimethoxytrityl)thymidine-3'-O-(2-  
cyanoethyl N,N-diisopropylphosphoramidite) in acetonitrile  
and a 0.4 M solution of 1H-tetrazole in acetonitrile is  
added, and allowed to react at room temperature for 5  
minutes. The product is washed with acetonitrile, and then a  
35 0.2 M solution of phenylacetyl disulfide in acetonitrile:3-

picoline (1:1 v/v) is added and allowed to react at room temperature for 3 minutes. This sulfurization step is repeated one more time for 3 minutes. The support is washed with acetonitrile, and then a solution of acetic  
5 anhydride/lutidine/THF (1:1:8), and N-methyl imidazole/THF is added to cap any unreacted 5'-hydroxyl group. The product is washed with acetonitrile.

This complete cycle is repeated five more times to produce the completely protected thymidine heptamer. The  
10 carrier containing the compound is treated with 30% aqueous ammonium hydroxide solution for 90 minutes at room temperature. The aqueous solution is filtered, and concentrated under reduced pressure to give a phosphorothioate heptamer, TTTTTTT.

## 15 **Example 2**

### **Synthesis of 5'-d(GACT)-3' phosphorothioate tetramer**

50 milligram (2  $\mu$ mole) of 5'-O-dimethoxytritylthymidine bound to CPG (controlled pore glass) through an ester linkage is taken up in a glass  
20 reactor, and a toluene solution of 3% dichloroacetic acid in toluene (volume/volume) is added to deprotect the 5'-hydroxyl group. The product is washed with acetonitrile. Then, a 0.2 M solution of 5'-O-(4,4'-dimethoxytrityl)thymidine-3'-O-(2-cyanoethyl N,N-diisopropylphosphoramidite) in acetonitrile and a 0.4 M  
25 solution of 1H-tetrazole in acetonitrile is added, and allowed to react at room temperature for 5 minutes. The product is washed with acetonitrile, and then a 0.2 M solution of phenylacetyl disulfide in acetonitrile:3-  
30 picoline (1:1 v/v) is added and allowed to react at room temperature for 3 minutes. This sulfurization step is repeated one more time for 3 minutes. The support is washed with acetonitrile and then a solution of acetic anhydride/lutidine/THF (1:1:8), and N-methyl imidazole/THF

030322 "2252050

is added to cap the unreacted 5'-hydroxyl group. The product is washed with acetonitrile.

A solution of 3% dichloroacetic acid in toluene (volume/volume) is added to deprotect the 5'-hydroxyl group. The product is washed with acetonitrile. Then, a 0.2 M solution of N<sup>4</sup>-benzoyl-5'-O-(4,4'-dimethoxytrityl)-2'-deoxycytidine-3'-O-(2-cyanoethyl N,N-diisopropylphosphoramidite) in acetonitrile and a 0.4 M solution of 1H-tetrazole in acetonitrile is added, and allowed to react at room temperature for 5 minutes. The product is washed with acetonitrile, and then a 0.2 M solution of phenylacetyl disulfide in acetonitrile:3-picoline (1:1 v/v) is added and allowed to react at room temperature for 3 minutes. This sulfurization step is repeated one more time for 3 minutes. The support is washed with acetonitrile and then a solution of acetic anhydride/lutidine/THF (1:1:8), and N-methyl imidazole/THF is added to cap any unreacted 5'-hydroxyl group. The product is washed with acetonitrile.

20 A solution of 3% dichloroacetic acid in toluene  
(volume/volume) is added to deprotect the 5'-hydroxyl group.  
The product is washed with acetonitrile. Then, a 0.2 M  
solution of N<sup>6</sup>-benzoyl-5'-O-(4,4'-dimethoxytrityl)-2'-  
deoxyadenosine-3'-O-(2-cyanoethyl N,N-  
25 diisopropylphosphoramidite) in anhydrous acetonitrile and a  
0.4 M solution of 1H-tetrazole in acetonitrile is added, and  
allowed to react at room temperature for 5 minutes. The  
product is washed with acetonitrile, and then a 0.2 M  
solution of phenylacetyl disulfide in acetonitrile:3-  
30 picoline (1:1 v/v) is added and allowed to react at room  
temperature for 3 minutes. This sulfurization step is  
repeated one more time for 3 minutes. The support is washed  
with acetonitrile and then a solution of acetic  
anhydride/lutidine/THF (1:1:8), and N-methyl imidazole/THF  
35 is added to cap the unreacted 5'-hydroxyl group. The product

is washed with acetonitrile.

A solution of 3% dichloroacetic acid in toluene (volume/volume) is added to deprotect the 5'-hydroxyl group. The product is washed with acetonitrile. Then, a 0.2 M solution of N<sup>2</sup>-isobutyryl-5'-O-(4,4'-dimethoxytrityl)-2'-deoxyguanosine-3'-O-(2-cyanoethyl N,N-diisopropylphosphoramidite) in acetonitrile and a 0.4 M solution of 1H-tetrazole in acetonitrile is added, and allowed to react at room temperature for 5 minutes. The product is washed with acetonitrile, and then a 0.2 M solution of phenylacetyl disulfide in acetonitrile:3-picoline (1:1 v/v) is added and allowed to react at room temperature for 3 minutes. This sulfurization step is repeated one more time for 3 minutes. The support is washed with acetonitrile and then a solution of acetic anhydride/lutidine/THF (1:1:8), and N-methyl imidazole/THF is added to cap any unreacted 5'-hydroxyl group. The product is washed with acetonitrile.

The carrier containing the compound is treated with 30% aqueous ammonium hydroxide solution for 90 minutes at room temperature and then incubated at 55 °C for 24 hour. The aqueous solution is filtered, concentrated under reduced pressure to give a phosphorothioate tetramer of 5'-dG-dA-dC-T-3'.

### Example 3

#### Synthesis of fully-modified 5'-d(TCC-CGC-CTG-TGA-CAT-GCA-TT)-3' phosphorothioate 20-mer

The synthesis of the above sequence was performed on a Pharmacia OligoPilot II Synthesizer on a 620 μmole scale using the cyanoethyl phosphoramidites and Pharmacia's primary support. Detritylation was performed using 3% dichloroacetic acid in toluene (volume/volume). Sulfurization was performed using a 0.2 M solution of phenylacetyl disulfide in acetonitrile:3-picoline (1:1 v/v)

for 2 minutes. At the end of synthesis, the support was washed with acetonitrile, treated with 30% aqueous ammonium hydroxide solution for 90 minutes at room temperature and then incubated at 55 C for 24 hours to give the product.

#### 5 **Example 4**

##### **Synthesis of fully-modified 5'-d(GCC-CAA-GCT-GGC-ATC-CGT-CA)-3' phosphorothioate 20-mer**

The synthesis of the above sequence was performed on a Pharmacia OligoPilot II Synthesizer on a 620  $\mu$ mole scale using the cyanoethyl phosphoramidites and Pharmacia's primar support. Detritylation was performed using 3% dichloroacetic acid in toluene (volume/volume). Sulfurization was performed using a 0.2 M solution of phenylacetyl disulfide in acetonitrile:3-picoline (1:1 v/v) for 2 minutes. At the end of synthesis, the support was washed with acetonitrile, treated with 30% aqueous ammonium hydroxide solution for 90 minutes at room temperature and then incubated at 55 C for 24 hours to give the product.

#### **Example 5**

##### **20 Synthesis of fully-modified 5'-d(GCG-TTT-GCT-CTT-CTT-CTT-GCG)-3' phosphorothioate 21-mer**

The synthesis of the above sequence was performed on a Pharmacia OligoPilot II Synthesizer on a 620  $\mu$ mole scale using the cyanoethyl phosphoramidites and Pharmacia's primar support. Detritylation was performed using 3% dichloroacetic acid in toluene (volume/volume). Sulfurization was performed using a 0.2 M solution of phenylacetyl disulfide in acetonitrile:3-picoline (1:1 v/v) for 2 minutes. At the end of synthesis, the support was washed with acetonitrile, treated with 30% aqueous ammonium hydroxide solution for 90 minutes at room temperature and then incubated at 55 C for 24 hours to give the product.



**Example 6****Synthesis of fully-modified 5'-d(GTT-CTC-GCT-GGT-GAG-TTT-CA)-3' phosphorothioate 20-mer**

The synthesis of the above sequence was performed on a Pharmacia OligoPilot II Synthesizer on a 620  $\mu$ mole scale using the cyanoethyl phosphoramidites and Pharmacia's primar support. Detritylation was performed using 3% dichloroacetic acid in toluene (volume/volume). Sulfurization was performed using a 0.2 M solution of phenylacetyl disulfide in acetonitrile:3-picoline (1:1 v/v) for 2 minutes. At the end of synthesis, the support was washed with acetonitrile, treated with 30% aqueous ammonium hydroxide solution for 90 minutes at room temperature and then incubated at 55 C for 24 hours to give the product.

**Example 7****Synthesis of fully-modified 5'-d(TCC-CGC-CTG-TGA)-2'-methoxyethyl-(CAT-GCA-TT)-3' phosphorothioate 20-mer**

The synthesis of the above sequence was performed on a Milligen 8800 Synthesizer on a 282  $\mu$ mole scale using cyanoethyl phosphoramidites and Pharmacia's primar support. Detritylation was performed using 3% dichloroacetic acid in toluene (volume/volume). Sulfurization was performed using a 0.4 M solution of phenylacetyl disulfide in acetonitrile:3-picoline (1:1 v/v) for 6 minutes. At the end of synthesis, the support was washed with acetonitrile, treated with 30% aqueous ammonium hydroxide solution for 90 minutes at room temperature and then incubated at 55 C for 24 hours to give the product.

**Example 8****Synthesis of fully-modified 5'-d(TCC-CGC-CTG-TGA)-2'-methoxyethyl-(CAT-GCA-TT)-3' phosphorothioate 20-mer**

The synthesis of the above sequence was performed on a

Pharmacia OligoPilot II Synthesizer on a 250  $\mu$ mole scale using the cyanoethyl phosphoramidites and Pharmacia's primar support. Detritylation was performed using 3% dichloroacetic acid in toluene (volume/volume). Sulfurization was

5 performed using a 0.4 M solution of phenylacetyl disulfide in acetonitrile:3-picoline (1:1 v/v) for 6 minutes. At the end of synthesis, the support was washed with acetonitrile, treated with 30% aqueous ammonium hydroxide solution for 90 minutes at room temperature and then incubated at 55 C for 24

10 hours to give the product.

It is intended that each of the patents, applications, printed publications, and other published documents mentioned or referred to in this specification be herein incorporated by reference in their entirety.

15 Those skilled in the art will appreciate that numerous changes and modifications may be made to the preferred embodiments of the invention and that such changes and modifications may be made without departing from the spirit of the invention. It is therefore intended that the

20 appended claims cover all such equivalent variations as fall within the true spirit and scope of the invention.

852020 262050

**WHAT IS CLAIMED IS:**

1. A method for the preparation of a phosphorus-linked oligomer comprising the steps of:
- (a) providing a solid support;
  - 5 (b) attaching a 5'-O-protected nucleoside to the solid support;
  - (c) deprotecting the 5'-hydroxyl of the nucleoside with a deprotecting reagent comprising a protic acid in a solvent to deprotect the 5'-hydroxyl of the nucleoside, the  
10 solvent being an aromatic solvent, an alkyl aromatic solvent, a halogenated aromatic solvent, a halogenated alkyl aromatic solvent, or an aromatic ether solvent;
  - (d) reacting the deprotected 5'-hydroxyl with an 5'-protected activated phosphorus compound to produce a  
15 covalent linkage therebetween;
  - (e) oxidizing or sulfurizing the covalent linkage to form a phosphodiester, phosphorothioate, phosphorodithioate or H-phosphonate linkage;
  - (f) repeating steps c through e at least once for  
20 subsequent couplings of additional activated phosphorus compounds, to produce the completed phosphorus-linked oligomer; and
  - (g) cleaving the oligomer from the solid support.
2. The method of claim 1 further comprising the step  
25 of capping remaining reactive sites with a solution containing a capping reagent.
3. The method of claim 1 wherein the oxidation or sulfurization step is performed after each iteration of steps (c) and (d).
- 30
4. The method of claim 1 wherein the oxidation or sulfurization step is performed after the final iteration of steps (c) and (d).
5. The method of claim 1 wherein the solvent in step

09032972.030299  
862020 2/26/06

(c) is an aromatic solvent, an alkyl aromatic solvent, or an aromatic ether.

6. The method of claim 1 wherein the solvent in step  
(c) is benzene, toluene, benzonitrile, *o*-, *m*- or *p*-xylene,  
5 mesitylene, or diphenyl ether.

7. The method of claim 6 wherein the solvent in step (c) is benzene, toluene or *o*-, *m*- or *p*-xylene.

8. The method of claim 7 wherein the solvent in step (c) is toluene.

10           9.    The method of claim 1 wherein the solvent in step  
          (c) is a halogenated aromatic solvent or a halogenated alkyl  
          aromatic solvent.

10. The method of claim 9 wherein the solvent in step (c) is chlorobenzene or benzotrifluoride.

15            11. The method of claim 1 wherein the activated  
phosphorus compound is an activated mononucleotide, an  
activated dinucleotide, or an activated polynucleotide.

12. The method of claim 1 wherein the activated phosphorus compound is a 5'-protected nucleoside phosphoramidite or a 5'-protected activated H-phosphonate nucleoside.

13. The method of claim 1 wherein the protecting group of the 5'-O-protected nucleoside and the 5'-protected activated phosphite compound is independently trityl, monomethoxy trityl, dimethoxytrityl, trimethoxytrityl, 2-chlorotrityl, DATE, TBTr, 9-phenylxanthine-9-yl (Pixyl) or 9-(p-methoxyphenyl)xanthine-9-yl (MOX).

14. The method of claim 13 wherein the protecting

group of the 5'-O-protected nucleoside and the 5'-protected activated phosphite compound is independently trityl, monomethoxy trityl, dimethoxy trityl, 9-phenylxanthine-9-yl (Pixyl) or 9-(p-methoxyphenyl)xanthine-9-yl.

- 5           15. The method of claim 14 wherein the protecting group of the 5'-O-protected nucleoside and the 5'-protected activated phosphite compound is dimethoxytrityl.

16. The method of claim 1 wherein the phosphorus-linked oligomer is a phosphodiester, phosphorothioate  
10 phosphorodithioate, or H-phosphonate oligonucleotide.

17. The method of claim 1 wherein the protic acid is formic acid, acetic acid, chloroacetic acid, dichloroacetic acid, trichloroacetic acid, trifluoroacetic acid, benzenesulfonic acid, toluenesulfonic acid, or  
15 phenylphosphoric acid.

18. The method of claim 1 wherein the solvent in step (c) further comprises an additive.

19. The method of claim 18 wherein the additive to the solvent in step (c) is an alcohol.

- 20           20. The method of claim 19 wherein the alcohol additive to the solvent in step (c) is from 0% to about 30% methanol, ethanol, 2-propanol, t-butyl alcohol, t-amyl alcohol, benzyl alcohol, or 1,1,1,3,3,3-hexafluoro-2-propanol, or a mixture thereof.

- 25           21. A method for the preparation of a phosphorus-linked oligomer comprising the steps of:
- a) providing a solid support;
  - b) attaching a 5'-O-protected nucleoside to the solid support;
  - 30           c) contacting the protected 5'-hydroxyl of the

5 halogenated alkyl aromatic solvent, or an aromatic ether solvent;

d) reacting the deprotected 5'-hydroxyl with a 5'-protected activated phosphite compound to produce a phosphite linkage;

10       e)     oxidizing or sulfurizing the phosphite linkage to  
form a phosphodiester, phosphorothioate, or  
phosphorodithioate linkage;

f) repeating steps c through e at least once for subsequent couplings of additional activated phosphite compounds, to produce the completed phosphorus-linked oligomer; and

g) cleaving the oligomer from the solid support.

22. The method of claim 21 further comprising the step  
of capping remaining reactive sites with a solution  
20 containing a capping reagent.

23. The method of claim 21 wherein the solvent in step (c) is an aromatic solvent, an alkyl aromatic solvent, or an aromatic ether.

24. The method of claim 23 wherein the solvent in step  
25 (c) is benzene, toluene, benzonitrile, *o*-, *m*- or *p*-xylene,  
mesitylene, or diphenyl ether.

25. The method of claim 24 wherein the solvent in step (c) is benzene, toluene or o-, m- or p-xylene.

26. The method of claim 25 wherein the solvent in step  
30 (c) is toluene.

27. The method of claim 21 wherein the solvent in step

(c) is a halogenated aromatic solvent or a halogenated alkyl aromatic solvent.

28. The method of claim 27 wherein the solvent in step (c) is chlorobenzene or benzonitrile.

5           29. The method of claim 21 wherein the activated phosphite compound is a mononucleotide phosphoramidite, a dinucleotide phosphoramidite, or a polynucleotide phosphoramidite.

30. The method of claim 21 wherein the protecting group of the 5'-O-protected nucleoside and the 5'-protected activated phosphite compound is independently trityl, monomethoxy trityl, dimethoxytrityl, trimethoxytrityl, 2-chlorotrityl, DATE, TBTr, 9-phenylxanthine-9-yl (Pixyl) or 9-(p-methoxyphenyl)xanthine-9-yl (MOX).

31. The method of claim 30 wherein the protecting group of the 5'-O-protected nucleoside and the 5'-protected activated phosphite compound is independently trityl, monomethoxy trityl, dimethoxy trityl, 9-phenylxanthine-9-yl (Pixyl) or 9-(p-methoxyphenyl)xanthine-9-yl.

20           32. The method of claim 31 wherein the protecting  
group of the 5'-O-protected nucleoside and the 5'-protected  
activated phosphite compound is dimethoxytrityl.

33. The method of claim 21 wherein the phosphorus-linked oligomer is a phosphodiester, phosphorothioate or a  
25 phosphorodithioate oligonucleotide.

34. The method of claim 21 wherein the protic acid is formic acid, acetic acid, chloroacetic acid, dichloroacetic acid, trichloroacetic acid, trifluoroacetic acid, benzenesulfonic acid, toluenesulfonic acid, or  
30 phenylphosphoric acid.

35. The method of claim 21 wherein the solvent in step (c) further comprises an additive.

36. The method of claim 35 wherein the additive to the solvent in step (c) is an alcohol.

5        37. The method of claim 36 wherein the alcohol additive to the solvent in step (c) is from 0% to about 30% methanol, ethanol, 2-propanol, *t*-butyl alcohol, *t*-amyl alcohol, benzyl lcohol, or 1,1,1,3,3,3-hexafluoro-2-propanol, or a mixture thereof.

10        38. The method of claim 22 wherein the solvent in step (c) is benzene, toluene, benzonitrile, *o*-, *m*- or *p*-xylene, mesitylene, or diphenyl ether; the activated phosphite compound is a mononucleotide phosphoramidite, a dinucleotide phosphoramidite, or a polynucleotide phosphoramidite; the  
15        protetcing group of the 5'-O-protected nucleoside and the 5'-protected activated phosphite compound is dimethoxytrityl; the phosphorus linked oligomer is a phosphodiester, phosphorothioate or a phosphorodithioate oligonucleotide; and the protic acid is dichloroacetic acid.


20        39. The method of claim 38 wherein the solvent in step (c) is toluene.

40. The method of claim 39 wherein the activated phosphite compound is a mononucleotide phosphoramidite.

25        41. The method of claim 1 wherein the 5'-protected activated phosphorus compound is a 5'-protected activated H-phosphonate compound; and the phosphorus-linked oligomer is a H-phosphonate oligonucleotide.

0503297.030298  
0503297.030298





## COMBINED DECLARATION AND POWER OF ATTORNEY

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name; and

I verily believe that I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled: **IMPROVED PROCESS FOR SYNTHESIS OF OLIGONUCLEOTIDES** the specification of which:

( ) is attached hereto.

(X) was filed on February 26, 1998 as Application Serial No. 09/032,972 and was amended on \_\_\_\_\_ (if applicable).

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose to the U.S. Patent and Trademark Office all information known to be material to the patentability of this application in accordance with 37 CFR § 1.56.

I hereby claim foreign priority benefits under 35 U.S.C. § 119 of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of any application on which priority is claimed:

Country	Number	Date Filed	Priority Claimed
_____	_____	_____	_____
_____	_____	_____	_____
_____	_____	_____	_____

552020"2622050

I hereby claim the benefit under 35 U.S.C. § 120 of any United States application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of 35 U.S.C. § 112, I acknowledge the duty to disclose to the U.S. Patent and Trademark Office all information known to be material to patentability as defined in 37 CFR § 1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application:

Application Serial No.	Filing Date	Status
------------------------	-------------	--------

--	--	--



I hereby appoint the following attorney(s) and/or agent(s) to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith: **John W. Caldwell** and **Michael P Straher**, Registration Nos. **28,937** and **38,325** of the firm of **WOODCOCK WASHBURN KURTZ MACKIEWICZ & NORRIS LLP**, One Liberty Place - 46th Floor, Philadelphia, Pennsylvania 19103, and **Herb Boswell**, **Laurel Bernstein** and **Andrew E. Granston**, Registration Nos. **27,311**, **37,280** and **38,473**, of **ISIS Pharmaceuticals**, 2292 Faraday Avenue, Carlsbad, California 92008.

Address all telephone calls and correspondence to:

**Michael P. Straher, Esq.**  
**WOODCOCK WASHBURN KURTZ MACKIEWICZ & NORRIS LLP**  
One Liberty Place - 46th Floor  
Philadelphia, PA 19103  
Telephone No. **215-568-3100**.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the

United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

1	Full Name: Achim H. Krotz	Inventor's Signature: 	Date: 4/15/98
	Residence: Irvine, California	Citizenship: U.S.	
	Post Office Address: 26 Pergola Irvine, California 92715		
2	Full Name: Vasulinga T. Ravikumar	Inventor's Signature: 	Date: 4/15/98
	Residence: Carlsbad, California	Citizenship: India	
	Post Office Address: 6606 Vireo Court Carlsbad, California 92009		
3	Full Name:	Inventor's Signature:	Date
	Residence:	Citizenship:	
	Post Office Address:		

DOCKET NO. ISIS-2710

PATENT



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

**In Re Application of:**

Achim H. Krotz and Vasulinga T. Ravikumar

**Serial No.:** 09/032,972

**Group Art Unit:** 1801

**Filed:** January 26, 1998

**Examiner:** Not Yet Assigned

**For:** IMPROVED PROCESS FOR  
SYNTHESIS OF OLIGONUCLEOTIDES

Assistant Commissioner for Patents  
Washington DC 20231

Sir:

**ASSOCIATE POWER OF ATTORNEY**

The undersigned, of the firm WOODCOCK WASHBURN KURTZ  
MACKIEWICZ & NORRIS LLP, One Liberty Place - 46th Floor, Philadelphia, Pennsylvania  
19103, Attorney and/or Agents for Applicant(s), hereby appoints the following:


Robert B. Washburn	Registration No. 16,574	David R. Bailey	Registration No. 35,057
Richard E. Kurtz	Registration No. 19,263	Barbara L. Mullin	Registration No. 38,250
John J. Mackiewicz	Registration No. 19,709	Lynn A. Malinoski	Registration No. 38,788
Norman L. Norris	Registration No. 24,196	Lori Y. Beardell	Registration No. 34,293
Albert W. Preston, Jr.	Registration No. 25,366	Doreen Yatko Trujillo	Registration No. 35,719
Dale M. Heist	Registration No. 28,425	Paul K. Legaard	Registration No. 38,534
Philip S. Johnson	Registration No. 27,200	Kevin M. Flannery	Registration No. 35,871
John W. Caldwell	Registration No. 28,937	David A. Cherry	Registration No. 35,099
Gary H. Levin	Registration No. 28,734	Anthony J. Rossi	Registration No. 24,053
Steven J. Rocci	Registration No. 30,489	Michael J. Swope	Registration No. 38,041
Dianne B. Elderkin	Registration No. 28,598	Michael J. Bonella	Registration No. P41,628
Francis A. Paintin	Registration No. 19,386	Harold H. Fullmer	Registration No. P42,560
John P. Donohue, Jr.	Registration No. 29,916	John E. McGlynn	Registration No. P42,863
Henrik D. Parker	Registration No. 31,863	Gail Ann Dalickas	Registration No. 40,979
Suzanne E. Miller	Registration No. 32,279	Kimberly R. Hild	Registration No. 39,224
Lynn B. Morreale	Registration No. 32,842	Lawrence A. Aaronson	Registration No. 38,369
Mark DeLuca	Registration No. 33,229	Jonathan M. Waldman	Registration No. 40,861
Joseph Lucci	Registration No. 33,307	Joseph R. Condo	Registration No. P42,431
Michael P. Dunnam	Registration No. 32,611	Michael K. Jones	Registration No. P41,100
Michael D. Stein	Registration No. 34,734		
Albert J. Marcellino	Registration No. 34,664		

and

Herb Boswell            Registration No. 27,311  
Laurel Bernstein       Registration No. 37,280  
Andrew E. Granston    Registration No. 38,473

of **ISIS PHARMACEUTICALS, INC.**, 2292 Faraday Avenue, Carlsbad, California 92008;  
his/her associates with full power to prosecute the above-identified application and to transact  
all business in the Patent Office connected therewith and requests that correspondence  
continue to be directed to the firm of **WOODCOCK WASHBURN KURTZ MACKIEWICZ  
& NORRIS LLP** at the above address.

Date: June 22, 1998

  
\_\_\_\_\_  
Michael P. Straher  
Registration No. 38,325

Woodcock Washburn Kurtz  
Mackiewicz & Norris LLP  
One Liberty Place - 46th Floor  
Philadelphia PA 19103  
Telephone: (215) 568-3100  
Facsimile: (215) 568-3439

© 1997 WWKMN



SCANNED 7

( ) application serial no. \_\_\_\_\_, filed \_\_\_\_\_

( ) patent no. \_\_\_\_\_, issued \_\_\_\_\_.

If the rights held by the above-identified small business concern are not exclusive, each individual, concern or organization having rights in the invention is listed below\* and no rights to the invention are held by any person, other than the inventor, who would not qualify as an independent inventor under 37 CFR 1.9(c) if that person made the invention, or by any concern which would not qualify as a small business concern under 37 CFR 1.9(d), or a nonprofit organization under 37 CFR 1.9(e).

**\*NOTE: Separate verified statements are required for each named person, concern or organization having rights to the invention averring to their status as small entities. (37 CFR 1.27)**

**FULL NAME:**

**ADDRESS:**

( ) INDIVIDUAL ( ) SMALL BUSINESS CONCERN ( ) NONPROFIT ORGANIZATION

**FULL NAME:**

**ADDRESS:**

( ) INDIVIDUAL ( ) SMALL BUSINESS CONCERN ( ) NONPROFIT ORGANIZATION

I acknowledge the duty to file, in this application or patent, notification of any change in status resulting in loss of entitlement to small entity status prior to paying, or at the time of paying, the earliest of the issue fee or any maintenance fee due after the date on which status as a small entity is no longer appropriate. (37 CFR 1.28(b))

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application, any patent issuing thereon, or any patent to which this verified statement is directed.

**NAME OF PERSON SIGNING**  
**TITLE OF PERSON SIGNING**  
**ADDRESS OF PERSON SIGNING**

Daniel L. Kisner  
President & Chief Operating Officer  
2292 Faraday Avenue  
Carlsbad, CA 92008

D. Kisner MD  
**SIGNATURE**

2/25/98  
**DATE**